American Association for Cancer Research
Browse

Figure S1 from Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy

Download (880.87 kB)
journal contribution
posted on 2024-03-15, 07:20 authored by Te-An Lee, En-Yun Tsai, Shou-Hou Liu, Shih-Duo Hsu Hung, Shing-Jyh Chang, Chi-Hong Chao, Yun-Ju Lai, Hirohito Yamaguchi, Chia-Wei Li
<p>The biological function of PD-1 on immune cells and cancer cells</p>

History

Related Materials

  1. 1.
    DOI - Is supplement to Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy

ARTICLE ABSTRACT

Activation of effector T cells leads to upregulation of PD-1, which can inhibit T-cell activity following engagement with its ligand PD-L1. Post-translational modifications (PTM), including glycosylation, phosphorylation, ubiquitination, and palmitoylation, play a significant role in regulating PD-1 protein stability, localization, and interprotein interactions. Targeting PTM of PD-1 in T cells has emerged as a potential strategy to overcome PD-1–mediated immunosuppression in cancer and enhances antitumor immunity. The regulatory signaling pathways that induce PTM of PD-1 can be suppressed with small-molecule inhibitors, and mAbs can directly target PD-1 PTMs. Preliminary outcomes from exploratory studies suggest that focusing on the PTM of PD-1 has strong therapeutic potential and can enhance the response to anti-PD-1.

Usage metrics

    Cancer Research

    Categories

    Keywords

    Gene RegulationPosttranscriptional and translational controlImmunotherapyBiomarkers for immunotherapyCheckpoint blockade

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC